Neonatology News
-
Ony Biotech Prepares For The Future
Dr. James Cummings has been an unofficial member of the ONY Biotech family since 1989, when he first started working at the Children’s Hospital of Buffalo. This month, it becomes official, as Dr. Cummings joins the ONY Biotech team as Chief Medical Officer, and the founder of the company and former Chief Medical Officer, Dr. Edmund Egan, steps into the role of Chief Scientific Officer. ...
By ONY Biotech
-
Honoring Ony’S Founder, Dr. Edmund Egan
Earlier this year, our founder and longtime Chief Medical Officer, Dr. Edmund Egan—known by many as Ted—announced his retirement after more than 37 years with the company. Dr. Egan was one of five scientists that founded ONY Biotech, then ONY, Inc., in 1985 in hopes of developing a lung surfactant to treat premature infants born with respiratory distress syndrome, known as RDS. A ...
By ONY Biotech
-
Enalare Therapeutics Receives Orphan Drug Designation From the U.S. FDA on ENA-001 for the Treatment of Apnea of Prematurity (AoP)
ENA-001, a New Chemical Entity (NCE) with a novel mechanism of action as an agnostic respiratory stimulant, has previously been granted Rare Pediatric Disease designation for the Treatment of AoP by the FDA, with eligibility for a priority review voucher (PRV). The compound is also being developed by Enalare for the treatment of post-operative respiratory depression and community drug overdose. ...
-
Annual General Meeting of Infant Bacterial Therapeutics
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2022, among other things, the following was resolved: to adopt the income statement and balance sheet and the consolidated income statement and consolidated balance sheet; that no dividend is made; discharge from liability granted to Board members and the managing director, that the Board shall consist of ...
-
Infant Bacterial Therapeutics publishes Annual Report for 2021
Infant Bacterial Therapeutics AB (publ) publishes today the Annual Report for 2021. The report is available on IBT’s website ibtherapeutics.com under the section “Investors & Media – Financial Reports” and is available in printed form for those that have requested. A copy can be requested by contacting IBT’s office via info@ibtherapeutics.com. About Infant ...
-
Enalare Therapeutics Receives Rare Pediatric Disease Designation for Lead Compound ENA-001 for the Treatment of Apnea of Prematurity
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life threatening critical care conditions, announced today that the Food and Drug Administration (FDA) has granted it's lead compound, ENA-001, rare pediatric disease designation for the treatment of Apnea of Prematurity. Enalare is planning to develop this unique agnostic ...
-
Neonatal Incubator Developed By MOm And Eg Technology Achieves First Clinical Use In The UK
Created by mOm Founder & CEO, James Roberts, and developed by mOm & the engineering team at eg technology, this innovative, lightweight incubator helped to sustain a premature baby’s life at St Peter’s Hospital, Chertsey. The mOm incubator was originally conceived to save the lives of premature babies in challenging, low/middle-income settings; as well as provide more options ...
-
Recruitment of the smallest infants in the Connection study paused
IBT started to recruit infants in Strata A (weight of 500g-749g) in The Connection Study on April 29 2021. Today, 68 infants have been recruited to the group. In accordance with the study protocol and clinical observations, enrolment of infants to Strata A has been paused awaiting a safety review by the Data Monitoring Committee (DMC). Subjects already randomized will continue treatment as per ...
-
Infant Bacterial Therapeutics receives additional patent protection in China
Infant Bacterial Therapeutics AB (IBT) today announces that the Chinese patent office has issued a decision to grant approval of IBTs patent application entitled: A method of activating lactic acid bacteria, which protects formulations of Lactobacillus reuteri including IBP-9414. IBT is currently developing its drug candidate IBP-9414 in Phase III for the prevention of NEC and improvement of ...
-
Recent microbiome study finds that Intus Bio’s products differentiate closely related gut bacteria in premature infants
Products from Intus Biosciences demonstrated high-resolution tracking of specific bacterial strains in a recent microbiome study, the results of which are being applied to better understand how pathogens and commensals become established in premature infants in neonatal intensive care units (NICU), with the goal of improving outcomes for premature infants. Intus Biosciences is a microbiome ...
-
New study reports activated B. infantis EVC001 feeding substantially reduces enteric inflammation, diaper rash and antibiotic use in preterm infants
Researchers publishing in the peer-review journal Frontiers in Pediatrics report that pre-term infants fed Bifidobacterium longum subsp. infantis (activated B. infantis EVC001) experienced significantly lower level of intestinal inflammation, 62% less diaper rash, and required 62% fewer antibiotics– all of which are critical health indicators in neonatal care. The study, Impact of ...
-
Study Results Are In On A Potential Non-Invasive Treatment For Rds
For little lungs everywhere, the families that love them, and the neonatologists who care for them, there’s news coming out of ONY Biotech, a family-focused neonatology pharmaceutical company. Today, ONY Biotech announced the results of a clinical trial on its aerosolized surfactant for newborns with respiratory distress syndrome (RDS), a disorder caused by lack of surfactant that can ...
By ONY Biotech
-
New Study: Infant Gut Health Must Focus on Microbiome Function, Not Diversity
The concepts of ecology, conservation, and restoration typically conjure images of natural woodlands, water systems and air quality. However, a new peer-reviewed perspective by Evolve BioSystems is taking a page from ecology playbooks in an effort to assist neonatologists and other pediatric health care professionals in assessing the state of the infant gut microbiome, which plays a significant ...
-
New Publication Concludes Gauss Surgical’s Triton System Associated with Earlier Postpartum Hemorrhage Intervention and Reduced Costs
Gauss Surgical, a health technology company, announced that a new study published in the International Journal of Obstetric Anesthesia concluded that the use of the company’s Triton system to monitor maternal blood loss during labor and delivery was associated with earlier postpartum hemorrhage intervention and cost savings. Researchers at Mount Sinai Hospital (New York, NY) studied over ...
-
Gauss Raises $20 Million in Series C From Northwell Health Softbank Ventures Korea for AI-Enabled Platform for the Operating Room
Gauss Surgical, an AI-driven healthcare technology company, raised $20 million in Series C funding from Northwell Health and SoftBank Ventures Korea, the global early-stage venture capital arm of SoftBank Group, as well as from the LS Polaris Innovation Fund and seven other leading US health systems. The proceeds of the round will be used to accelerate the adoption of its Triton platform in ...
-
New mechanism of Elafin to prevent lung injury in mechanically ventilated newborns
tiakis BIOTECH AG today announced the publication of research results by Alcazar et al. from Stanford University on a new mechanism by which Elafin rescues lung cell survival in the lung of newborn mice subjected to mechanical ventilation. Neonatal chronic lung disease or bronchopulmonary dysplasia develops in preterm infants whose lungs are incompletely developed and therefore require ...
-
Microbial Outbreak Results in Deaths at Neonatal Intensive Care Unit
Cinnaminson, NJ, August 8th, 2012 The Health Minister of the Bahamas recently ordered an investigation into an outbreak of a microbial pathogen at a neonatal intensive care unit. The outbreak, caused by a type of bacteria known as Acinetobacter baumannii, is believed to have sickened eight infants and caused two of the infants to die. Outbreaks of Acinetobacter baumannii in healthcare ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you